Yubo International Biotech Files 8-K/A Amendment
Ticker: YBGJ · Form: 8-K/A · Filed: Jan 10, 2025 · CIK: 895464
| Field | Detail |
|---|---|
| Company | Yubo International Biotech Ltd (YBGJ) |
| Form Type | 8-K/A |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, accountant-change, financial-statements
TL;DR
Yubo International Biotech filed an amendment to its 8-K, updating its accountant and financial docs.
AI Summary
Yubo International Biotech Ltd. filed an amendment (8-K/A) on January 10, 2025, regarding events as of December 30, 2024. The filing primarily concerns changes in the registrant's certifying accountant and includes financial statements and exhibits. The company was formerly known as Magna Lab Inc. and changed its name on July 22, 1994.
Why It Matters
This amendment updates information regarding Yubo International Biotech's certifying accountant and financial disclosures, which is crucial for investors to understand the company's financial reporting and auditor relationships.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report and primarily concerns administrative changes related to the company's accountant and financial statements, with no immediate indication of significant new risks.
Key Players & Entities
- Yubo International Biotech Ltd (company) — Registrant
- Magna Lab Inc (company) — Former company name
- December 30, 2024 (date) — Date of earliest event reported
- January 10, 2025 (date) — Filing date
FAQ
What is the primary purpose of this 8-K/A filing?
The primary purpose of this 8-K/A filing is to report changes in the registrant's certifying accountant and to include financial statements and exhibits.
What was Yubo International Biotech Ltd. formerly known as?
Yubo International Biotech Ltd. was formerly known as Magna Lab Inc.
When did Yubo International Biotech Ltd. change its name?
The company changed its name on July 22, 1994.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is December 30, 2024.
Where is Yubo International Biotech Ltd.'s principal executive office located?
The principal executive offices are located at Room 105, Building 5, 31 Xishiku Avenue, Xicheng District, Beijing, China, 100034.
Filing Stats: 937 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-01-10 06:01:54
Filing Documents
- yubo_8k.htm (8-K/A) — 27KB
- 0001640334-25-000050.txt ( ) — 151KB
- yubo-20241230.xsd (EX-101.SCH) — 6KB
- yubo-20241230_lab.xml (EX-101.LAB) — 14KB
- yubo-20241230_cal.xml (EX-101.CAL) — 1KB
- yubo-20241230_pre.xml (EX-101.PRE) — 9KB
- yubo-20241230_def.xml (EX-101.DEF) — 2KB
- yubo_8k_htm.xml (XML) — 4KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On December 26, 2024, Yubo International Biotech Limited, a New York corporation (the "Company"), dismissed Michael T. Studer CPA P.C. ("MTS CPA") as the Company's independent registered public accounting firm in light of the retirement of Mr. Studer, the president of MTS CPA. The dismissal was approved by the board of directors (the "Board") of the Company and became effective on January 2, 2025. MTS CPA's report on the financial statements of the Company for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, nor was such report qualified or modified as to uncertainty, audit scope, or accounting principle, other than an explanatory paragraph regarding the Company's ability to continue as a going concern. During the Company's fiscal years ended December 31, 2023 and December 31, 2022 and the subsequent interim period from January 1, 2024 to December 26, 2024, (i) there were no disagreements with MTS CPA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of MTS CPA, would have caused MTS CPA to make reference to the subject matter of the disagreements in connection with its report, and (ii) there were no "reportable events" as such term is defined in Item 304(a)(1)(v) of Regulation S-K. The Company has requested that MTS CPA furnish to the Company a letter addressed to the U.S. Securities and Exchange Commission stating whether or not MTS CPA agrees with the above statements. A copy of such letter, dated January 6, 2025, is filed as Exhibit 16.1 to this current report on Form 8-K. (b) Engagement of New Independent Registered Public Accounting Firm On December 30, 2024, the Company engaged HHL LLP ("HHL") as its new independent registered public accountant, effecti
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter from Michael T. Studer CPA P.C. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 10, 2025 Yubo International Biotech Limited By: /s/ Lina Liu Name: Lina Liu Title: Chief Financial Officer 3